{"id":"hmi-115","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HMI-115 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing the suppressive signal that tumors use to evade the immune system. By blocking the PD-L1/PD-1 axis, the drug restores T-cell activation and proliferation, enabling the immune system to recognize and attack cancer cells more effectively.","oneSentence":"HMI-115 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:59.999Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation)"}]},"trialDetails":[{"nctId":"NCT05101317","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Hope Medicine (Nanjing) Co., Ltd","startDate":"2021-10-11","conditions":"Endometriosis","enrollment":142},{"nctId":"NCT07318688","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated Pain","status":"NOT_YET_RECRUITING","sponsor":"Hope Medicine (Nanjing) Co., Ltd","startDate":"2026-03-01","conditions":"Endometriosis","enrollment":540},{"nctId":"NCT06118866","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Hope Medicine (Nanjing) Co., Ltd","startDate":"2023-09-11","conditions":"Androgenetic Alopecia","enrollment":192},{"nctId":"NCT05324293","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period","status":"COMPLETED","sponsor":"Hope Medicine (Nanjing) Co., Ltd","startDate":"2022-05-11","conditions":"Androgenetic Alopecia","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HMI-115","genericName":"HMI-115","companyName":"Hope Medicine (Nanjing) Co., Ltd","companyId":"hope-medicine-nanjing-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HMI-115 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}